Kamada Ltd. (KMDA.TA) Announces Initiation Of A Phase 2 U.S. Clinical Trial Of Inhaled AAT To Treat Alpha-1 Antitrypsin Deficiency
3/24/2014 7:49:04 AM
NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces the initiation of a new Phase 2 U.S. clinical trial of its proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD, or Inherited Emphysema).
Help employers find you! Check out all the jobs and post your resume.
comments powered by